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The number of deaths and prevalent cases of cirrhosis are increasing worldwide, but 5 
there are no licensed antifibrotic or pro-regenerative medicines and liver transplantation 6 
is a limited resource. Cirrhosis is characterized by extreme liver fibrosis, organ 7 
dysfunction and complications related to portal hypertension. Advances in our 8 
understanding of liver fibrosis progression and regression following successful 9 
etiological therapy betray vulnerabilities in common and disease-specific mechanisms 10 
that could be targeted pharmacologically. 11 
Area Covered 12 
This review summarizes the cellular and molecular pathogenesis of cirrhosis as a 13 
preface to discussion of the current drug development landscape. The dominant 14 
indication for global pharma R&D pipelines is cirrhosis related to non-alcoholic 15 
steatohepatitis (NASH). We searched Clinicaltrials.gov, GlobalData, Pharmaprojects 16 
and PubMed for pertinent information on emerging synthetic drugs for cirrhosis, with a 17 
focus on compounds listed in phase 2 and phase 3 trials. 18 
Expert Opinion 19 
Although cirrhosis can regress following successful etiological treatment, there are no 20 
specific antifibrotic or pro-regenerative drugs approved for this condition. Obstacles to 21 
drug development in cirrhosis include intrinsic biological factors, a heterogeneous 22 
patient population and lack of acceptable surrogate endpoints. Nevertheless, several 23 
synthetic drugs are being evaluated in clinical trials and the NASH field is rapidly 24 
embracing a drug combination approach. 25 
 26 
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 30 
1. BACKGROUND 31 
Cirrhosis is characterized by extreme liver scarring (fibrosis), loss of organ function and 32 
serious complications related to portal hypertension (high blood pressure in the hepatic 33 
portal vein and its branches). It represents a generic end-stage for a variety of chronic 34 
liver diseases (CLD) including non-alcoholic fatty liver disease (NAFLD), alcohol-related 35 
liver disease and chronic viral hepatitis. NAFLD is now the commonest etiology 36 
worldwide, affecting 1 in 4 adults [1], and the progressive form that leads to patient harm 37 
(non-alcoholic steatohepatitis (NASH)) is predicted to increase by 63% between 2015 38 
and 2030 [2], representing a global cohort of at least 100 million individuals. Cirrhosis is 39 
typically classified as either compensated or decompensated. In compensated cirrhosis 40 
the liver can maintain its important functions and patients are generally asymptomatic. 41 
In decompensated cirrhosis the liver no longer functions adequately, and patients 42 
develop life-threatening problems including bleeding varices (varicose veins in the 43 
esophagus), ascites (abnormal buildup of fluid in the abdomen) and hepatic 44 
encephalopathy (altered brain function). 45 
Cirrhosis is a growing healthcare challenge worldwide. The Global Burden of Disease 46 
Study 2017 reported that there were 112 million prevalent cases of compensated 47 
cirrhosis, 10.6 million prevalent cases of decompensated cirrhosis, and more than 1.32 48 
million deaths caused by cirrhosis (33.3% in females and 66.7% in males) [3].  For 49 
NASH, the number of prevalent cases more than doubled for compensated cirrhosis 50 
and more than tripled for decompensated cirrhosis between 1990-2017 [3]. Crucially, 51 
cirrhosis impairs health-related quality of life (HRQoL) [4] and typically affects people of 52 
working age, meaning that there are also broad socio-economic impacts. 53 
Although 90% of cirrhosis is due to preventable causes, three-quarters of people are 54 
diagnosed at a late stage when the impact of lifestyle changes (e.g., weight loss, 55 
alcohol abstinence) or etiological treatment (e.g., antiviral therapy) is attenuated. Liver 56 
transplantation is the most effective therapeutic option for end-stage liver disease but is 57 
a scarce resource. There are currently no Food and Drug Administration (FDA) or 58 
European Medicines Agency (EMA) approved antifibrotic or pro-regenerative drug 59 
therapies for cirrhosis. However, there is intense activity in drug development, 60 
especially for liver fibrosis and cirrhosis related to NASH. In this article, we review the 61 
current drug development landscape in cirrhosis, with a specific focus on emerging 62 
synthetic drugs that are being evaluated in phase 2 or phase 3 trials. 63 
 64 
2. MEDICAL NEED 65 
The transition from compensated cirrhosis to decompensated cirrhosis occurs at a rate 66 
of about 5% to 7% per year [5]. Once decompensation has occurred, cirrhosis becomes 67 
a systemic disease with multi-organ involvement associated with a dysregulated 68 
inflammatory state [6]. Decompensation represents a key prognostic inflection point in 69 
the natural history of CLD, as the median survival drops from more than 12 years for 70 
compensated cirrhosis to about 2 years for decompensated cirrhosis [5]. Accordingly, 71 
treatment strategies in cirrhosis may vary depending on the disease stage as well as 72 
the underlying etiology (Figure 1). Broadly, the goals of treatment for compensated 73 
cirrhosis are to slow, halt or reverse progression of fibrosis and prevent 74 
decompensation events, whereas for decompensated cirrhosis the focus is on 75 
preventing further decompensation and death (e.g., by improving liver function) and 76 
treating complications related to portal hypertension. Importantly, any treatment strategy 77 
in cirrhotic patients should not increase the risk of hepatocellular carcinoma (HCC) and, 78 
consistent with FDA guidance, should ultimately improve how a patient ‘feels, functions 79 
or survives’. In the absence of specific antifibrotic or pro-regenerative drug therapies, 80 
liver transplant is the only available option for end-stage disease. Liver transplantation 81 
consistently improves outcomes in cirrhosis, including HRQoL measures, but this may 82 
not necessarily apply to pharmacological agents. Other clinical endpoints are also likely 83 
to be meaningful in patients with decompensated cirrhosis, such as the rates of 84 
hospitalization, unscheduled clinic and emergency room visits, tests performed, and lost 85 
work days [7].  86 
Another urgent requirement for drug development in advanced CLD (aCLD), particularly 87 
NASH, is validation of non-invasive liver tests that can accurately stratify disease 88 
severity, track changes in disease activity/stage and, crucially, are acceptable 89 
surrogates of future clinically meaningful outcomes (e.g., decompensation, death). This 90 
is now a global effort driven by large European (LITMUS) and US consortia (NIMBLE). 91 
A crowded field of emerging candidates includes serum markers/panels and imaging 92 
markers  all with varying strengths and limitations [8]. Although invasive assessment of 93 
portal hypertension by hepatic venous pressure gradient (HVPG) measurement is the 94 
best predictor of complications and mortality in patients with aCLD [9], no non-invasive 95 
test is sufficiently validated to supplant HVPG.  96 
 97 
3. EXISTING TREATMENTS 98 
Existing treatments in cirrhosis comprise established etiological therapies (to remove 99 
the underlying drivers of disease), treatments for specific complications of hepatic 100 
decompensation and liver transplantation.  101 
3.1 Curing or controlling the primary disease  102 
Eradication of the etiological factor(s) causing liver injury is the foundational treatment 103 
strategy for all patients with aCLD and is, currently, the only effective antifibrotic 104 
approach [10]. Successful etiological treatment (e.g., response to antiviral drugs in 105 
chronic HBV or HCV, weight loss, alcohol abstinence) has been shown to ameliorate 106 
portal hypertension, prevent decompensation and improve outcome in patients with 107 
compensated cirrhosis [11-15]. However, results in patients with decompensated 108 
cirrhosis are generally less consistent, even after etiological cure [16-18].  109 
Together, these studies have provided important proof of principle that fibrosis 110 
regression in cirrhosis is feasible and is associated with improved patient outcomes. In 111 
a substantial proportion of patients with cirrhosis, however, treatment of the underlying 112 
cause is either ineffective or not possible; these individuals are potential candidates for 113 
antifibrotic therapies. Etiological treatment studies have also shown that remodeling of 114 
fibrosis in aCLD is a slow process. Following bariatric surgery in NASH, reduction of 115 
fibrosis began during the first year but continued through 5 years [19]. Likewise, 116 
reversal of fibrosis/cirrhosis in patients with chronic hepatitis B treated with entecavir 117 
was generally only evident in long-term (3-7 years) follow-up biopsies [20], indicating 118 
that it could take several years to demonstrate efficacy of an antifibrotic drug in clinical 119 
trials that rely on a biopsy endpoint. 120 
3.2 Treatments for specific complications of decompensated cirrhosis  121 
There are a multitude of established treatments for specific complications of 122 
decompensated cirrhosis (including ascites, variceal hemorrhage and hepatic 123 
encephalopathy) that are beyond the scope of this article.  As decompensated cirrhosis 124 
is now considered a systemic disease, with multi-organ pathology associated with 125 
dysregulated inflammation, a number of mechanistic approaches have been explored to 126 
prevent disease progression in patients with decompensated cirrhosis, including i) 127 
targeting microbiome abnormalities and bacterial translocation (e.g., rifaximin); ii) 128 
improving abnormal circulatory function (e.g., long-term albumin); iii) treating the 129 
inflammatory milieu (e.g., statins); and iv) targeting portal hypertension (e.g., non-130 
selective beta-blockers) [21]. In particular, there has been considerable interest in the 131 
therapeutic potential of statins in patients with aCLD [22]. Statins decrease the activity 132 
of small GTPases (Rho, Ras) and their downstream signaling pathways in the liver and 133 
have been shown to reduce portal pressure, improve endothelial dysfunction, attenuate 134 
fibrogenesis, protect against acute-on-chronic liver failure (ACLF) and HCC [23,24]. An 135 
active phase 4 trial (STATLiver; NCT04072601) is examining the effect of atorvastatin 136 
on survival and hospitalizations. A further phase 2 multicenter European trial 137 
(LIVERHOPE_EFFICACY; NCT03780673) is investigating the combination of 138 
simvastatin plus rifaximin in patients with decompensated cirrhosis to prevent ACLF 139 
development.  140 
3.3 Liver transplantation  141 
Around 8,000 liver transplants were performed in the US alone in 2019, with estimated 142 
associated healthcare costs of $878,400 per transplant [25]. Outcomes are generally 143 
excellent, with overall 1-year and 5-year patient survival for adult elective deceased-144 
donor first liver transplants of around 94% and 83%, respectively [26]. However, 145 
because of a shortfall of deceased-donor organs to meet growing demand, around 25% 146 
of people on the waiting list die before receiving a transplant. NASH is the most rapidly 147 
increasing indication for liver transplantation in the US (and is now the leading indication 148 
in women) [27].  149 
 150 
4. MARKET REVIEW  151 
There is no reliable drug intelligence data to estimate the overall liver cirrhosis market 152 
size (i.e., including all cirrhosis etiologies). This would require comprehensive 153 
epidemiological data for all CLD and would need to account for/exclude drugs that are 154 
used to target earlier disease stages prior to cirrhosis. In terms of NASH related 155 
cirrhosis, GlobalData are currently anticipating that 27% of the 7 major NASH markets 156 
($7.3B; US, 5EU, and Japan) will be accounted for by cirrhosis (fibrosis stage F4) 157 
patients by 2029. The forecasted drugs targeting F4 patients in 2029 include: Ocaliva® 158 
(obeticholic acid), CC-90001, aldafermin, belapectin, Ozempic® (semaglutide) and 159 
BMS-986036. 160 
 161 
5. CURRENT RESEARCH GOALS 162 
Two major research goals in cirrhosis are the development of effective therapies to 163 
improve clinically meaningful patient outcomes and the identification and validation of 164 
noninvasive biomarkers.  165 
Drug discovery and development approaches for liver fibrosis and cirrhosis are 166 
becoming ever more sophisticated, leveraging human ‘big data’ resources [28] and 167 
incorporating high-throughput methods to investigate novel drugs/combinations (e.g., 168 
liver-on-a-chip devices, hepatic organoids/spheres) [29]. Increasingly, preclinical 169 
efficacy assays with closer proximity to the patient (e.g., precision-cut human liver slices 170 
[30]) are being sought to obviate some of the shortcomings of animal models and 171 
increase confidence for clinical translation.   172 
Validated non-invasive biomarkers are urgently sought for both therapeutic trials and 173 
clinical practice, to identify ‘high risk’ populations (i.e., patients with advanced fibrosis), 174 
to provide prognostic information, and for monitoring treatment response. There is 175 
consensus that the field must move beyond liver biopsy to determine drug effects and 176 
although there have been great strides in this area, no new technologies have yet been 177 
deemed acceptable by regulators to replace histological assessment of fibrosis. Tests 178 
that show promise as surrogate efficacy endpoints include imaging measures (e.g., 179 
Magnetic Resonance Imaging-Proton Density Fat Fraction (MRI-PDFF), MR 180 
elastography, iron-corrected T1 relaxation (cT1)) and serum markers (e.g., AST/ALT, 181 
Enhanced Liver Fibrosis (ELF) test, PRO-C3). Critically, recent trial data demonstrate 182 
that biomarkers track the histological regression of fibrosis and therefore may be 183 
suitable for monitoring drug response [31-34]. If liver biopsy is performed, evaluation 184 
using artificial intelligence (AI)-based digital pathology is increasingly recommended to 185 
extract more information that is objective and quantitative [35]. In patients with cirrhosis, 186 
tests that can reliably measure changes in liver function (e.g., HepQuant SHUNT test 187 
[36]) or portal hypertension [37] are also a high priority. Notably, HVPG has recently 188 
been used as a primary outcome measure in trials in cirrhosis due to NASH (e.g., 189 
simtuzumab, belapectin), but the FDA have not yet approved reduction in HVPG as an 190 
accepted endpoint for registration trials in cirrhosis. 191 
 192 
6. SCIENTIFIC RATIONALE 193 
Data from rodent models and a variety of successfully treated human liver diseases has 194 
demonstrated unequivocally that liver fibrosis is reversible and even established 195 
cirrhosis can regress substantially. Moreover, our understanding of the key cellular and 196 
molecular players that mediate fibrogenesis, sinusoidal “capillarization” and 197 
microcirculatory dysfunction, in addition to regression of fibrosis and liver regeneration 198 
in different liver diseases has revealed specific targets for newly developed or 199 
repositioned antifibrotic drug candidates [38].  200 
Although there are important disease-specific nuances (see sub-section on 201 
‘Pathogenesis of NASH’), common mechanisms have been identified that pertain to all 202 
CLD [39]. A central event in liver fibrosis is the activation of hepatic stellate cells (HSC), 203 
by various inflammatory stimuli, to myofibroblast-like cells that are proliferative, 204 
contractile, immunomodulatory and synthesize excessive amounts of scar extracellular 205 
matrix (ECM). Consequently, the activation, function and fate of HSC are prominent 206 
targets for antifibrotic therapies [40]. In animal models, proof of principle for a variety of 207 
mechanistic treatments has been demonstrated, such as deactivation of HSC [41], 208 
reduced proliferation of HSC [42], decreased ECM deposition [43] or removal of 209 
activated HSC via forced apoptosis [44].  210 
In response to liver injury, liver sinusoidal endothelial cells (LSECs) also rapidly de-211 
differentiate, acquiring a so-called “capillarized” phenotype that is characterized by loss 212 
of fenestrae, development of a basement membrane, reduced nitric oxide bioavailability 213 
and production of proinflammatory, profibrogenic and vasoconstrictor factors that 214 
dysregulate neighboring cells (especially HSC) and alter the sinusoidal microcirculation 215 
[45,46]. The LSEC and associated sinusoidal communications are therefore also a 216 
prime target for antifibrotic and portal hypertension therapy.   217 
Hepatic macrophages have also been identified as key regulators of both fibrogenesis 218 
and fibrosis regression. Whereas conditional depletion of ‘scar-associated 219 
macrophages’ during liver injury in mice was antifibrotic, their removal during the 220 
resolution phase of liver injury impaired tissue repair [47]. Circulating Li6Chi monocytes 221 
have been identified as the source of profibrogenic hepatic macrophages in murine liver 222 
fibrosis [48]. However, following injury removal, these cells undergo a phenotypic switch 223 
to a restorative macrophage phenotype that release matrix metalloproteinases (MMPs) 224 
to promote fibrotic ECM degradation, as well as factors that dampen the inflammatory 225 
response and drive liver regeneration [49]. Although comparative data in humans is 226 
limited [50], hepatic macrophages have emerged as antifibrotic drug targets, for 227 
example through inhibiting the infiltration of inflammatory monocytes (e.g., CCR2/CCR5 228 
antagonism [51]) or disrupting the activity of macrophage-derived factors (e.g., galectin-229 
3 (gal-3)) [52]. Thus far, therapeutic strategies that promote macrophage polarization to 230 
a restorative phenotype in situ, have only been examined in rodent models [53].  231 
In established cirrhosis, the mature hepatic scar is less susceptible to remodeling due to 232 
a number of factors including lysyl oxidase (LOX) mediated ECM cross-linking and a 233 
paucity of scar-associated cells (myofibroblasts and macrophages) capable of secreting 234 
matrix metalloproteinases (MMPs). Critically, the ECM is not an inert structural 235 
framework; instead, ECM components and tissue stiffness actively modulate the 236 
phenotype and proliferation of the cells that are embedded or closely associated with it. 237 
Accordingly, ECM molecules, their receptors (e.g., αv integrins) and ECM cross-linking 238 
enzymes have been investigated as therapeutic targets. Altering the balance between 239 
ECM degrading MMPs and their specific inhibitors (tissue inhibitor of metalloproteinases 240 
(TIMPs)), for example using MMP gene therapy [54]), is also potentially antifibrotic but 241 
has only been shown in preclinical models. 242 
Finally, it is clear that any successful therapy in cirrhosis must improve liver function. 243 
Hepatic regeneration is a feature of non-fibrotic healthy liver, but severe fibrosis 244 
represses regeneration. In mice, remodelling of ECM is required for a robust hepatic 245 
progenitor cell response [55]. However, it is not known if an effective antifibrotic drug in 246 
patients with cirrhosis will be sufficient to unleash the liver’s inherent regenerative 247 
potential. Exploring the complex relationship between regeneration and fibrosis in the 248 
liver may identify new therapeutic approaches to augment liver function as a potential 249 
alternative to liver transplantation [56].  250 
6.1 Pathogenesis of NASH 251 
The pathogenesis of NASH is represented as a model of substrate-overload liver injury, 252 
with genetic and environmental (e.g., microbiome-related) risk factors modifying disease 253 
susceptibility and progression [57]. Indeed, the microbiome plays a major role in NAFLD 254 
progression through different mechanisms, including immune activation via toll-like 255 
receptors and potentially endogenous alcohol production by the gut bacteria [58]. 256 
Modulation of the microbiome may play a role in our future therapeutic armamentarium, 257 
but more precision will be required in how to target it. 258 
Free fatty acids are central to NASH development and originate from lipolysis of 259 
triglycerides in adipose tissue or from de novo lipogenesis (excess sugars converted to 260 
fatty acids) in the liver. When the catabolism of fatty acids through beta-oxidation or 261 
formation of triglyceride (TG) is overwhelmed, fatty acids can contribute to the 262 
generation of lipotoxic species that cause endoplasmic reticulum (ER) stress, oxidative 263 
stress and inflammasome activation. These processes induce hepatocellular injury, 264 
inflammation, HSC activation and progressive accumulation of scar ECM. Elucidating 265 
these disease-specific pathways has provided a rational basis for drug development in 266 
pre-cirrhotic and cirrhotic NASH. 267 
 268 
7. COMPETITIVE ENVIRONMENT 269 
7.1 Search strategy 270 
We searched for recent and active phase 2 and phase 3 clinical trials of synthetic drugs 271 
for the treatment of liver cirrhosis using ClinicalTrials.gov GlobalData and Citeline's 272 
Pharmaprojects. We focused on drugs directed against mechanistic targets rather than 273 
etiological therapies (such as antiviral drugs for chronic hepatitis B and C) or treatments 274 
for specific complications of cirrhosis. Background literature was explored using 275 
PubMed. Drug structures and chemical formulas were sourced from PubChem (an open 276 
chemistry database at the National Institutes of Health (NIH)). 277 
 278 
7.2 Recent unsuccessful clinical trials in cirrhosis due to NASH 279 
Before considering current clinical trial activity, it is important and informative to reflect 280 
on the disappointing results from recent major studies in cirrhosis due to NASH 281 
(summarized in Table 1). These setbacks have highlighted several potential issues 282 
including the poor predictivity of preclinical models; inadequate duration of trials in 283 
cirrhosis that may require several years for substantial fibrosis remodeling to occur; 284 
drug mechanism of action which may be unfavorable in cirrhosis (or insufficient as 285 
monotherapy); lack of adequate biomarkers of target engagement; heterogeneous 286 
patient population; sampling variability of liver biopsy; and high placebo response rate. 287 
7.2.1 Simtuzumab 288 
Simtuzumab (GS-6624) is a subcutaneously (SC) administered humanized IgG4 289 
monoclonal antibody, developed by Gilead Sciences, that specifically binds and inhibits 290 
lysyl oxidase like 2 (LOXL2), an enzyme that is thought to mediate collagen crosslinking 291 
in fibrosis. Initial enthusiasm for this approach was based on compelling evidence of 292 
both human tissue expression and preclinical data implicating LOXL2 in the 293 
pathogenesis of fibrosis in liver, lung and tumor xenograft models [59]. However, the 294 
drug failed in phase 2b clinical trials as a monotherapy in patients with bridging fibrosis 295 
and compensated cirrhosis due to NASH [60] and in compensated liver disease due to 296 
primary sclerosing cholangitis (PSC) [61]. Although development of simtuzumab has 297 
been terminated, this may have been a target engagement issue and there could still be 298 
a role for small molecule inhibitors of LOXL2 (and/or other isoforms), possibly deployed 299 
earlier in fibrosis to slow progression rather than to reverse advanced disease. 300 
7.2.2 Selonsertib 301 
Selonsertib is an orally administered apoptosis signal-regulating kinase 1 (ASK1) 302 
inhibitor, also developed by Gilead Sciences. In the setting of oxidative stress, activation 303 
of ASK1, a serine/threonine signaling kinase, can lead to phosphorylation of p38 304 
mitogen-activated protein kinase and c-Jun N-terminal kinase (JNK), leading in turn to 305 
activation of stress response pathways that worsen hepatic inflammation, apoptosis, 306 
and fibrosis. Moreover, hepatic steatosis, fibrosis and TGFβ1 expression was 307 
significantly attenuated in ASK1-deficient mice fed a high-fat diet [62]. However, 308 
selonsertib failed in two large and well-powered phase 3 trials in patients with advanced 309 
fibrosis (STELLAR 3) and compensated cirrhosis (STELLAR 4) due to NASH [63]. 310 
Although selonsertib had dose-dependent effects indicating pharmacodynamic activity, 311 
and statistically non-significant improvements in noninvasive biomarkers were 312 
observed, it did not reach the primary efficacy endpoint of fibrosis improvement without 313 
worsening of NASH at week 48. The drug is still being explored in combination 314 
regimens (where efficacy might be amplified), but it is no longer being pursued as a 315 
monotherapy.  316 
7.2.3 Emricasan 317 
Emricasan is an orally administered pan caspase inhibitor developed by Conatus and 318 
Novartis. Inhibition of caspases may reduce the disease-driven loss of hepatocytes and 319 
production of apoptotic bodies and microparticles that promote progression of CLD. 320 
Moreover, emricasan was recently shown to improve liver sinusoidal microvascular 321 
dysfunction and portal hypertension in cirrhotic rats [64]. However, despite showing 322 
pharmacodynamic effects on caspase inhibition, emricasan was ineffective in multiple 323 
phase 2 trials, including in patients with pre-cirrhotic NASH [65] and compensated [66] 324 
and decompensated [67] NASH related cirrhosis. Interestingly, in a subgroup of patients 325 
with HVPG ≥16 mmHg in the ENCORE-PH study, there was a significant reduction of 326 
HVPG, suggesting efficacy in a more severe population [66]. Nevertheless, following 327 
multiple setbacks, development of emricasan has been terminated.  328 
7.2.4 Belapectin 329 
Belapectin (GR-MD-02) is an intravenously (IV) administered gal-3 inhibitor under 330 
development by Galectin Therapeutics. Gal-3 is the most important galectin protein 331 
secreted in the disease state, mainly by macrophages, and it binds to the cell surface 332 
and ECM glycans to regulate a variety of physiological and pathological processes 333 
including cell apoptosis, adhesion, migration, angiogenesis, and inflammatory 334 
responses. Belapectin is a complex carbohydrate drug that improved pathology of 335 
NASH and reversed liver fibrosis/cirrhosis in animal models [68]. However, in a phase 2 336 
trial in patients with compensated NASH cirrhosis and HVPG ≥6 mmHg (NASH-CX), 337 
belapectin failed the primary endpoint of a reduction in HVPG in the total population 338 
[69]. Nevertheless, in a post hoc analysis, patients without varices at baseline had a 339 
significantly reduced HVPG and lower incidence of varices development in the drug-340 
treated group compared to placebo, although interestingly there was no dose-response 341 
effect. These results should be viewed cautiously and are now being validated in a 342 
further phase 2b/3 trial in NASH cirrhosis (NCT04365868).   343 
 344 
7.3 Synthetic drugs currently being investigated in phase 2 or phase 3 trials for 345 
cirrhosis: monotherapy landscape 346 
A number of drugs are currently in development for cirrhosis, predominantly due to 347 
NASH, and these are summarized in Table 2 and Figure 2. 348 
7.3.1 Obeticholic acid 349 
Obeticholic acid (INT-747) is an orally administered synthetically-modified analog of 350 
chenodeoxycholic acid, under development by Intercept Pharmaceuticals as a first-in-351 
class farnesoid X receptor (FXR) agonist for the treatment of primary biliary cholangitis 352 
(PBC) and NASH. FXR agonism has multifaceted effects on bile acid metabolism, 353 
FGF19 induction, gut microbiota, hepatic inflammation and fibrogenesis. It is an 354 
established modality for improving NASH histological endpoints, including fibrosis, and 355 
several steroidal and non-steroidal FXR ligands are in development [70]. The results of 356 
the REGENERATE trial (NCT02548351) in patients with pre-cirrhotic NASH [71] was 357 
hailed as a watershed moment in NASH drug development as this was the first positive 358 
phase 3 clinical trial in patients with NASH and stage 2-3 fibrosis. However, after 18 359 
months of obeticholic acid treatment, fibrosis improvement (≥1 stage) was only 360 
observed in 23% of all drug-treated patients (compared to 12% on placebo) and there 361 
was no effect on NASH resolution. In June 2020, the FDA rejected a New Drug 362 
Application (NDA) for obeticholic acid because “the predicted benefit based on a 363 
surrogate histopathologic end point remains uncertain and does not sufficiently 364 
outweigh the potential risks”. Major adverse effects related to FXR agonists include 365 
pruritus and increased low‐density lipoprotein (LDL) cholesterol (LDL-C), both of which 366 
are dose-dependent, and decreased high-density lipoprotein cholesterol. Since 367 
cardiovascular disease is common (and is the leading cause of death) in patients with 368 
NAFLD, this rise in serum LDL-C is noteworthy. The relative impact on long-term 369 
outcomes of dyslipidemia associated with OCA therapy, compared to the observed 370 
histological benefit, remains undefined [72]. However, if approved, it is likely that OCA 371 
will require regular monitoring of lipid profiles and treatment with statin therapy as 372 
indicated.  373 
Intercept remains committed to the drug and a phase 3 trial (REVERSE; NCT03439254) 374 
is ongoing in patients with compensated NASH cirrhosis, with the primary endpoint of a 375 
one-stage reduction in fibrosis without worsening of NASH.  376 
7.3.2 Cenicriviroc 377 
Cenicriviroc (TAK-652; TBR-652) is an orally administered small molecule dual 378 
antagonist of CC-motif chemokine receptors 2 and 5 (CCR2/5), under development by 379 
AbbVie (Allergan before acquisition) for the treatment of NASH and liver fibrosis. The 380 
recruitment of inflammatory monocytes and macrophages via CCR2 and lymphocytes 381 
and HSCs via CCR5 promotes the progression of NASH to fibrosis. In preclinical 382 
models of chronic liver injury, cenicriviroc reduced monocyte/macrophage accumulation 383 
in the liver and ameliorated fibrosis [73]. However, the observation that CCR2 deficient 384 
mice are protected from experimental fibrosis but are also unable to effectively resolve 385 
fibrosis [74], likely reflects the importance of hepatic macrophages in remodeling scar 386 
and may indicate that anti-inflammatory treatments such as cenicriviroc are best applied 387 
during early/progressive fibrosis.  388 
In a phase 2b trial (CENTAUR; NCT02217475) in patients with NASH and fibrosis stage 389 
1-3, cenicriviroc improved fibrosis [32], leading on to a large phase 3 trial (AURORA; 390 
NCT03028740) in patients with NASH and stage 2/3 fibrosis; topline results are 391 
imminent. Additionally, there is an open-label rollover study to assess the long-term 392 
safety of continued treatment with cenicriviroc in participants who completed CENTAUR 393 
or AURORA as a result of reaching an adjudicated liver-related clinical outcome (either 394 
histological progression to cirrhosis, MELD score >15, ascites needing treatment, or 395 
hospitalization for variceal bleed, encephalopathy or spontaneous bacterial peritonitis).    396 
7.3.3 Pegbelfermin 397 
Pegbelfermin (BMS‐986036; ARX-618) is a SC administered polyethylene glycol‐398 
modified (PEGylated) recombinant human fibroblast growth factor 21 (FGF21) analog, 399 
under development by Bristol-Myers Squibb, with a prolonged half‐life designed to 400 
support up to weekly dosing. FGF21 is a hormone involved in the regulation of glucose, 401 
lipids, and energy homeostasis. In rodents and primates, the half-life of recombinant 402 
FGF21 is approximately 1–2 h, therefore multiple approaches have been employed to 403 
engineer FGF21 to extend its duration of action. Preclinical studies suggest that FGF21 404 
binds to the FGFR1/Klothoβ complex in adipose tissue, leading to elevated secretion of 405 
the insulin-sensitizing hormone adiponectin, although additional metabolic pathways 406 
may also be affected [75]. The mechanism(s) behind the hepatic anti-inflammatory and 407 
anti-fibrotic effects of FGF21 are unclear but could be mediated via the strong increase 408 
in adiponectin. In a phase 2 trial (NCT02097277) in patients with obesity and type 2 409 
diabetes, 12 weeks pegbelfermin treatment was associated with improved metabolic 410 
parameters and serum fibrosis markers [76]. A subsequent phase 2a study 411 
(NCT02413372) of overweight/obese patients with NASH and fibrosis stage 1-3, 412 
showed a significant decrease in absolute hepatic fat fraction (MRI-PDFF) in the group 413 
receiving 10 mg pegbelfermin daily (−6·8% vs −1·3%) and in the group receiving 20 mg 414 
pegbelfermin weekly (−5·2% vs −1·3%) compared with the placebo group [77]. Both 415 
pegbelfermin and efruxifermin (discussed below) are well tolerated. The most common 416 
side effects of FGF21 treatment are gastrointestinal (GI)-related (increased frequency of 417 
diarrhea and nausea). A potential effect of FGF21 on bone mineral density will require 418 
further studies of longer duration. Pegbelfermin also induces anti-drug antibodies, which 419 
can cross-react with the endogenous FGF21, so this may need to be carefully 420 
monitored. Pegbelfermin is currently being studied in phase 2b trials in pre-cirrhotic 421 
NASH (FALCON 1; NCT03486899) and in compensated NASH cirrhosis (FALCON 2; 422 
NCT03486912) with the primary endpoint of a one-stage reduction in fibrosis without 423 
worsening of NASH. However, since the antifibrotic effects of pegbelfermin are not well 424 
documented, its potential efficacy in NASH cirrhosis is uncertain.  425 
7.3.4 Efruxifermin  426 
Efruxifermin (AKR-001) is a SC administered human immunoglobulin 1 (IgG1) Fc-427 
FGF21 fusion protein, engineered for sustained systemic pharmacologic exposure, 428 
under development by Akero Therapeutics for the treatment of NASH. In a phase 1 trial 429 
(NCT01856881) it showed sustained pharmacodynamic effects on insulin sensitivity and 430 
lipid metabolism in type-2 diabetes patients [78]. The BALANCED study 431 
(NCT03976401) is an ongoing phase 2a dose-ranging trial of weekly SC efruxifermin 432 
treatment for up to 16 weeks in NASH patients with fibrosis stage 1-4. The primary 433 
endpoint is the change from baseline in hepatic fat fraction assessed by MRI-PDFF at 434 
week 12. In March 2020, the company reported data from the week 12 analysis, 435 
showing that all efruxifermin dose groups saw highly statistically significant absolute 436 
reductions in liver fat (12-15%, compared to 0% for placebo), relative reductions in liver 437 
fat (63-72%, compared to 0% for placebo) and reduction in ALT (24-32 U/L, compared 438 
to 6U/L for placebo). In June 2020, the company reported data for the 40 treatment 439 
responders who had end-of-treatment biopsies at week 16, showing that 48% had 440 
fibrosis improvement of at least one stage without worsening of NAS across all dose 441 
groups, with a 62% response rate for the 50 mg dose group. Meaningful improvements 442 
in weight loss, dyslipidemia and glycemic control were also observed at week 16. A 443 
dose-dependent increase in plasma adiponectin was observed in all dose levels. 444 
Although results for efruxifermin have been encouraging, and among the strongest 445 
fibrosis changes reported in NASH so far, data from the compensated cirrhosis cohort is 446 
not yet available.  447 
7.3.5 Aldafermin 448 
Aldafermin (NGM–282) is a SC administered engineered non-tumorigenic analog of 449 
human fibroblast growth factor 19 (FGF19) under development by NGM 450 
biopharmaceuticals for the treatment of NASH, PBC and PSC. Aldafermin acts on two 451 
receptor complexes, FGFR1c-KLB and FGFR4-KLB. FGFR1c-KLB activation reduces 452 
liver steatosis and increases insulin sensitivity, while FGFr4-KLB suppresses 453 
expression of CYP7A1, which encodes the rate limiting enzyme in de novo bile acid 454 
synthesis. Therefore, aldafermin may ameliorate dysregulated bile acid metabolism 455 
(and thereby attenuate hepatobiliary injury) as well as regulating metabolic 456 
homoeostasis [79]. In a phase 2 trial (NCT02704364) in patients with PSC, 6% of whom 457 
had compensated cirrhosis, NGM282 potently inhibited bile acid synthesis and 458 
decreased serum fibrosis markers (ELF score and Pro-C3), without significantly 459 
affecting alkaline phosphatase (ALP) levels [80]. In contrast, aldafermin reduced ALP in 460 
a phase 2 trial (NCT02026401) in patients with PBC, although no assessment was 461 
made of its impact on fibrosis [81]. In a phase 2 trial (NCT02443116) in patients with 462 
NASH, treatment with aldafermin for up to 24 weeks decreased absolute liver fat 463 
content (measured by MRI-PDFF), improved histological features of NASH and reduced 464 
ELF score and Pro-C3 levels [31,82]. Across studies, aldafermin has been generally 465 
well tolerated, but is associated with dose-related abdominal cramping and diarrhea. A 466 
significant observed increase in plasma LDL-C is a potential concern that may require 467 
counterregulatory treatment with statins. Further phase 2 trials evaluating its efficacy in 468 
patients with stage 2/3 fibrosis (ALPINE 2/3; NCT03912532) and compensated cirrhosis 469 
(ALPINE 4; NCT04210245) due to NASH are ongoing.  470 
7.3.6 BMS-986263  471 
BMS-986263 (ND-L02-s0201) is an IV administered vitamin A-coupled lipid nanoparticle 472 
(LNP) containing small interfering ribonucleic acid (siRNA) against HSP47, under 473 
development by Bristol-Myers Squibb. HSP47 is an ER-localized collagen-specific 474 
molecular chaperone indispensable for the correct folding of procollagen in the ER. 475 
Increased expression of HSP47 is associated with excessive accumulation of collagens 476 
in scar tissues of various experimental and human fibrotic diseases. BMS-986263 is 477 
targeted to HSC via retinoid-containing moieties conjugated to the LNP surface and, by 478 
silencing HSP47, may halt or reverse liver fibrosis by disrupting collagen synthesis [43]. 479 
In a phase 2 trial (NCT03420768) in 61 patients with advanced liver fibrosis due to 480 
chronic HCV who had achieved sustained virological response, once-weekly IV infusion 481 
of BMS-986263 for 12 weeks was generally well tolerated, demonstrated target 482 
engagement by reducing liver HSP47 mRNA levels and reduced histological fibrosis, 483 
mostly in those with cirrhosis [83]. A phase 2 study (NCT04267393) to evaluate the 484 
safety and efficacy of BMS-986263 in patients with compensated NASH cirrhosis is now 485 
planned. 486 
7.3.7 CC-90001   487 
CC-90001 (CC-539) is an orally active JNK1 inhibitor (12.9-fold more potent for JNK1 488 
inhibition than JNK2 in vitro) under development by Bristol-Myers Squibb (Celgene 489 
before acquisition) for the treatment of idiopathic pulmonary fibrosis (IPF), liver fibrosis 490 
and NASH. JNK activity regulates various pathophysiologic processes, including 491 
hepatocyte death, steatosis, inflammation and insulin resistance, which are associated 492 
with NASH, fibrosis and HCC. JNK is involved in HSC activation and fibrogenesis in 493 
animal models and in patients with liver fibrosis due to chronic HCV and NASH [84]. 494 
Moreover, Jnk1 knockout mice are protected from liver fibrosis. Available 495 
pharmacodynamic and safety data on CC-90001 are limited. In a phase 1b study in IPF 496 
(NCT02510937), CC-90001 treatment caused a trend to reduction in plasma tenascin-C 497 
levels [85]. The most common side effects were GI in nature (all mild to moderate). CC-498 
90001 is currently being investigated in a phase 2 dose-finding study (NCT04048876) in 499 
patients with NASH and fibrosis stage 3 or 4 (cirrhosis), to evaluate its safety and 500 
efficacy, with a primary endpoint of a ≥1 stage improvement in liver fibrosis after one 501 
year of treatment. 502 
7.3.8 Semaglutide 503 
Semaglutide (NN-9535) is a long-acting once-weekly SC administered human 504 
glucagon-like peptide 1 (GLP-1) receptor agonist, under development by Novo Nordisk. 505 
The discovery of GLP-1, an incretin hormone with important effects on glycemic control 506 
and body weight regulation, led to efforts to synthesize GLP-1 analogs with increased 507 
half-life for the treatment of type-2 diabetes, obesity and NASH [86]. Semaglutide is 508 
approved for the treatment of type-2 diabetes, whilst different formulations of liraglutide 509 
are approved for the treatment of type-2 diabetes and chronic weight management. 510 
Encouragingly, GLP-1 analogs also positively affect cardiovascular outcomes in patients 511 
with type-2 diabetes, probably through modified atherosclerotic progression by an anti-512 
inflammatory mechanism [87]. In a recent phase 2 trial (NCT02970942) of 320 patients 513 
with NASH and stage 2/3 fibrosis, 72 weeks of semaglutide treatment at the highest 514 
dose resulted in a significantly higher percentage of patients with NASH resolution than 515 
placebo (59% versus 17%) [88]. The trial did not show a significant between-group 516 
difference in the percentage of patients with an improvement in fibrosis stage, although 517 
improvements in noninvasive markers of fibrosis were observed with semaglutide 518 
treatment. Semaglutide has no direct liver effects (lack of GLP1 receptor in the liver) so 519 
all the benefits are driven by weight loss. The drug is associated with less hunger and 520 
food cravings, better control of eating and a lower preference for high-fat foods [89]. The 521 
amount of weight loss achieved is greater than that seen with any licensed anti-obesity 522 
drug. Semaglutide also has a favorable effect on both TG and LDL-C. Dose related GI 523 
side effects (nausea, constipation, and vomiting) have been reported across trials of 524 
semaglutide. It is currently in a phase 2 trial (NCT03987451) in 65 patients with NASH 525 
and compensated liver cirrhosis, to evaluate its safety and efficacy compared with 526 
placebo. Importantly, the development of an oral formulation of semaglutide may help to 527 
improve treatment adherence in the future. 528 
7.3.9 Firsocostat 529 
Firsocostat (ND-630; GS-0976) is an acetyl CoA carboxylase (ACC) allosteric inhibitor, 530 
under development by Nimbus Apollo (part of Gilead Sciences). Inhibition of ACC 531 
reduced hepatic lipotoxicity, blocked the activation of TGF-β-induced collagen 532 
production in HSCs by inhibiting de novo lipogenesis (DNL), and significantly reduced 533 
fibrosis in 4 models of NASH [90]. In a recent phase 2 trial in patients with NASH and 534 
fibrosis (F1-3), GS-0976 20 mg daily for 12 weeks decreased liver fat (MRI-PDFF) by 535 
29% and reduced levels of the serum fibrosis marker TIMP-1 [91]. However, increases 536 
in circulating TG are a known mechanistic consequence of hepatic ACC inhibition so 537 
long-term cardiovascular effects require further investigation. Although the phase 2b 538 
ATLAS trial (NCT03449446) was unsuccessful, the firsocostat-cilofexor combination 539 
was superior to placebo in reducing liver stiffness and serum markers of fibrosis in 540 
patients with bridging fibrosis and cirrhosis due to NASH [92]. Gilead are continuing to 541 
evaluate firsocostat in combination regimens (NCT02781584). 542 
7.3.10 Cilofexor 543 
Cilofexor (GS-9674) is an orally administered gut-restricted nonsteroidal FXR agonist 544 
under development by Gilead Sciences for the treatment of NASH, PBC and PSC. 545 
Intestinal FXR agonism by cilofexor augments the physiological release of FGF19, and 546 
this could mitigate potential deleterious effects of systemic FXR activation (as seen with 547 
OCA), including dyslipidemia, pruritus, and hepatotoxicity. Cilofexor has demonstrated 548 
anti‐inflammatory and antifibrotic effects and reduced portal pressure in a rat model of 549 
NASH [93]. In a phase 2 trial (NCT02854605) in patients with NASH, cilofexor for 24 550 
weeks was generally well-tolerated and caused significant reductions in hepatic 551 
steatosis and liver biochemistry [94]. Moderate to severe pruritus was more common in 552 
patients receiving cilofexor 100 mg (14%) than in those receiving cilofexor 30 mg (4%) 553 
and placebo (4%). However, cilofexor did not cause significant changes in lipid 554 
parameters. As mentioned previously, cilofexor is being evaluated in combination with 555 
firsocostat in patients with advanced fibrosis/cirrhosis due to NASH. In addition, there is 556 
a phase 1 open label study (NCT04060147) to assess the safety and tolerability of 557 
escalating doses of cilofexor in patients with PSC and compensated cirrhosis.  558 
7.3.11 Tocotrienol 559 
Tocotrienol is a natural vitamin E supplement. Vitamin E has potent anti-inflammatory 560 
and antioxidant properties which may reduce liver injury in NAFLD. Gamma‐tocotrienol 561 
supplementation attenuated hepatic inflammation and fibrosis in experimental NASH 562 
models, through a synergistic mechanism of decreased de novo lipogenesis and 563 
hepatic ER stress [95]. In a previous study, oral tocotrienol treatment increased hepatic 564 
tocotrienol content and attenuated the time-dependent rise in MELD score in patients 565 
with end stage liver disease/cirrhosis [96]. A current phase 2 randomized placebo-566 
controlled trial (NCT02581085) of daily tocotrienol treatment for 3 years is being 567 
undertaken to validate the observed effect on Model For End-Stage Liver Disease 568 
(MELD) score in patients with cirrhosis. 569 
7.3.12 PRI-724 570 
PRI-724 is a small molecule cAMP-response element binding protein (CBP)/β-catenin 571 
inhibitor under development by Prism Pharma and Ohara Pharmaceutical for the 572 
treatment of liver fibrosis/cirrhosis, solid tumors and leukemia. Wingless-related 573 
integration site (Wnt)/β-catenin signaling is a highly conserved evolutionary pathway 574 
that regulates key cellular functions including proliferation, differentiation, migration, 575 
genetic stability, apoptosis, and stem cell renewal. Aberrant Wnt/β-catenin signaling has 576 
been implicated in fibrosis in a number of organs including the lung, kidney, skin, and 577 
liver. In liver, CBP/β-catenin inhibitors mediate antifibrotic effects through inhibition of 578 
HSC activation and increased resolution of inflammation by macrophages [97]. PRI-724 579 
has shown antifibrotic efficacy in various experimental liver fibrosis models including 580 
HCV transgenic (HCV-Tg) mice, carbon tetrachloride toxicity, bile-duct ligation and 581 
NASH related liver injury [98]. A phase 1 clinical trial (NCT02195440) of IV administered 582 
PRI-724 demonstrated its safety, tolerability and preliminary efficacy in patients with 583 
HCV-induced cirrhosis. Currently, a phase 1/2a trial (NCT03620474) is investigating the 584 
pharmacokinetics, safety and antifibrotic efficacy of twice-weekly IV PRI-724 for 12 585 
weeks in patients with cirrhosis due to chronic hepatitis B or C.  586 
7.3.13 Carbamazepine 587 
Carbamazepine (Tegretol®; Novartis) is a sodium channel blocker that is FDA approved 588 
for the treatment of epilepsy, trigeminal neuralgia and bipolar disorder. However, it was 589 
also shown to act as an autophagy-enhancing drug that decreased the hepatic load of 590 
mutant alpha1-antitrypsin Z (ATZ) and hepatic fibrosis in a mouse model of AT 591 
deficiency-associated liver disease [99]. The drug is now being investigated in a phase 592 
2 trial (NCT01379469) in patients with severe liver disease and portal hypertension 593 
caused by AT deficiency to evaluate effects on ATZ load (primary outcome) and hepatic 594 
fibrosis, HVPG and MELD score (secondary outcomes). 595 
7.3.13 Erlotinib 596 
Erlotinib hydrochloride (Tarceva®; Genentech) is an orally administered inhibitor of the 597 
intracellular phosphorylation of tyrosine kinase associated with the epidermal growth 598 
factor receptor (EGFR). It is FDA approved for the treatment of non-small cell lung 599 
cancer. In 3 different rodent models of progressive cirrhosis, erlotinib reduced the total 600 
number of activated HSCs, decreased hepatocyte proliferation and, consequently, 601 
attenuated fibrosis and the development of HCC [42,100]. A phase 1/2 academic-602 
sponsored pilot study (NCT02273362) of erlotinib in patients with Child-Pugh class A 603 
cirrhosis, to evaluate effects on fibrogenesis and development of HCC, is closed to 604 
enrolment but results are not yet available.  605 
 606 
7.4 Synthetic drugs currently being investigated in phase 2 or phase 3 trials for 607 
cirrhosis: combination therapy landscape 608 
As the number of headstones in the ‘NASH graveyard’ continues to grow, drug 609 
developers are shifting focus to combination regimens. The rationale is that the efficacy 610 
of treatment for conditions such as NASH and fibrosis, with complex inter-related 611 
pathogenic pathways, may be enhanced by using combinations of drugs that target 612 
different and complementary mechanisms. Indeed, the impact of an antifibrotic or anti-613 
inflammatory therapy may be attenuated if unrestrained upstream metabolic drivers 614 
remain unchecked. Ideally, combinations should also have positive effects beyond the 615 
liver such as weight loss, cardiovascular protection, insulin sensitization and lipid 616 
reduction. However, there are potential downsides such as safety, tolerability (although 617 
drug combination could actually decrease side effects), cost and a more challenging 618 
route to regulatory approval. Important topics include the optimal selection of drugs for 619 
combination (possibly using computational methods), chronology (i.e., overlapping, 620 
outlasting or additive), identification of patient populations that might benefit from 621 
combination regimens as first-line treatment, and trial design.  Although the phase 2 622 
ATLAS trial of firsocostat, cilofexor and selonsertib (Table 1) did not meet its primary 623 
endpoint (possibly due to a small sample size), the complex interactions between drugs 624 
in different combination regimens will continue to inform future development [101]. For 625 
example, data from the phase 2a proof-of-concept trial of firsocostat, cilofexor and 626 
semaglutide in pre-cirrhotic NASH (NCT03987074) was recently reported [102]. This 627 
combination seems logical. Whilst firsocostat increases TG and cilofexor increases 628 
LDL-C, semaglutide has a favorable effect on both TG and LDL-C; in addition, 629 
firsocostat/cilofexor may boost the therapeutic effects of semaglutide. The positive 630 
safety/tolerability data and exploratory biomarker improvements observed for hepatic 631 
steatosis and liver injury will be investigated further in a phase 2b trial in compensated 632 
NASH cirrhosis patients. Theoretically, a palette of different combinations would allow 633 
tailoring of treatment according to the predominant pathophysiological drivers, stage of 634 
NASH and existing co-morbidities (i.e., personalized therapy). 635 
 636 
8. POTENTIAL DEVELOPMENT ISSUES 637 
8.1 Placebo response rate in NASH trials 638 
One key observation from recent trials in NASH is the striking placebo response rate. In 639 
the recently published phase 2 trial (NCT02970942) of semaglutide in patients with 640 
NASH and stage 1-3 fibrosis, an improvement in fibrosis was reported in 33% of 641 
placebo-treated patients [88]. This raises concern that biopsy staging of fibrosis is not a 642 
sufficiently accurate longitudinal surrogate biomarker and may obscure the detection of 643 
a beneficial drug effect. A high placebo response rate also necessitates larger trials to 644 
guarantee adequate power to detect a significant difference between placebo and 645 
intervention arms. Application of AI-augmented histological quantification methods or, 646 
ideally, accurate non-invasive surrogate biomarkers may help to parse out truly dynamic 647 
changes from sampling variability. In addition, standardization of lifestyle management 648 
plans within and across therapeutic trials in NASH may also help to reduce the placebo 649 
response, as recently recommended by the Liver Forum's Standard of Care Working 650 
Group [103].  651 
 652 
8.2 Regulatory considerations 653 
The FDA currently supports commercial drug development in patients with NASH and 654 
significant fibrosis (≥ F1 but ≤ F4) and with NASH and compensated cirrhosis, as these 655 
individuals are at higher risk for liver-related adverse clinical outcomes. However, the 656 
latest FDA draft guidance (June 2019) [104] has important implications for drug 657 
development and current trials in compensated cirrhosis related to NASH. Crucially, 658 
only a composite clinical outcomes endpoint is deemed acceptable for approval. At 659 
present the FDA questions the feasibility of pharmacological reversal of cirrhosis in 660 
NASH and is unconvinced about the relationship between histological changes in 661 
cirrhosis and clinical outcomes. Ongoing trials in compensated NASH cirrhosis include 662 
the phase 3 trial of obeticholic acid (REVERSE; NCT03439254) and the phase 2b/3 trial 663 
of belapectin (NCT04365868) that have primary endpoints of a one-stage reduction in 664 
fibrosis and prevention of esophageal varices, respectively. The current draft FDA 665 
guidance indicates that these endpoints would be insufficient for accelerated approval in 666 
compensated NASH cirrhosis. This draft guidance provides a clear roadmap for the 667 
future and should expedite research to validate surrogate endpoints in cirrhosis 668 
populations.  669 
 670 
9. CONCLUSION 671 
Although there are no approved antifibrotic drugs for cirrhosis, there is significant 672 
investment and drug development activity in the NASH space. As a therapeutic 673 
indication, cirrhosis poses many challenges. Ultimately, optimal therapies in cirrhosis 674 
need to go beyond fibrosis regression and impact meaningful clinical endpoints. 675 
Accordingly, parallel development of non-invasive biomarkers that accurately correlate 676 
with therapeutic response and that are predictive of outcomes are priorities for the field.  677 
 678 
10. EXPERT OPINION 679 
This review of emerging synthetic drugs for the treatment of cirrhosis, overwhelmingly in 680 
NASH, indicates a continued search for efficacious pharmacotherapies targeting diverse 681 
mechanisms. However, recent prominent terminated programs attest to the challenge of 682 
cirrhosis as an indication. The new FDA guidance provides a framework for future 683 
studies in NASH related compensated cirrhosis, with the objective of preventing 684 
decompensation events and subsequent liver transplant and liver-related mortality. The 685 
current NASH-centric approach has drawbacks, however, for the wider cirrhosis 686 
population. Among all cirrhosis deaths in 2017, 50% were alcohol related. Alcohol 687 
related cirrhosis remains an under-explored indication, but the disease burden 688 
reinforces the importance of developing more generic antifibrotic medicines.  689 
The coming years will see increasing use of next-generation technologies, such as 690 
‘omics-driven target and drug discovery and the evolution of precision medicine to 691 
determine patient subpopulations with different risk of disease progression and drug 692 
response profiles. In NASH, genome-wide association studies have identified variants in 693 
genes including patatin-like phospholipase domain-containing protein 3 (PNPLA3), 694 
transmembrane 6 superfamily member 2 (TM6SF2) and hydroxysteroid 17β 695 
dehydrogenase 13 (HSD17B13) that may predict individual risk of developing advanced 696 
disease [105]. Novel prognostic genetic markers are also potential drug targets. For 697 
example, a loss-of-function variant in the HSD17B13 gene is protective against NASH 698 
and adverse outcomes among NASH patients. Alnylam Pharmaceuticals have 699 
developed an siRNA therapeutic approach designed to mimic the genetic loss of 700 
HSD17B13 that is currently being evaluated in a phase 1 trial (NCT04565717). 701 
The identification of optimal participants for pharmacotherapy trials is particularly 702 
relevant in cirrhosis. Even ‘compensated cirrhosis’ could encompass a very 703 
heterogeneous cohort (i.e., extending from some patients at the F3/F4 interface to 704 
others with clinically significant portal hypertension and varices; Figure 1). Early 705 
cirrhosis without varices might be a better disease stage, theoretically, to demonstrate 706 
cirrhosis reversal. 707 
Marketing approval for a synthetic drug in cirrhosis does not seem imminent and there 708 
are relatively few agents in active phase 2/3 trials (Table 2). Although results from the 709 
phase 3 trial of obeticholic acid in NASH cirrhosis (REVERSE; NCT03439254) are 710 
keenly anticipated, hopes should be tempered by the fact that efficacy was only modest 711 
in pre-cirrhotic NASH and fibrosis in cirrhosis appears, so far, recalcitrant to therapy. 712 
Indeed, companies may avoid cirrhosis as an indication and focus on pre-cirrhotic 713 
NASH, or even target an alternative organ altogether (e.g., IPF) where the path to 714 
registration is better defined and potentially easier to achieve.  715 
Of course, drugs that are shown to be effective at earlier stages of disease may also be 716 
beneficial in cirrhosis. Promising agents continue to emerge in pre-cirrhotic NASH, such 717 
as the pan-peroxisome proliferator-activated receptor (pan-PPAR) agonist lanifibranor, 718 
which showed encouraging effects against fibrosis and portal hypertension in preclinical 719 
models [106]. Furthermore, data was recently reported from Inventia’s phase 2b trial in 720 
non-cirrhotic NASH (NATIVE; NCT03008070) showing positive effects of lanifibranor 721 
(IVA337) on histological endpoints (NASH resolution and fibrosis regression) [107]. 722 
Nevertheless, for pre-cirrhotic and cirrhotic NASH, the field appears to be moving 723 
inexorably towards drug combination therapy, for example a metabolic focused drug 724 
(e.g., insulin sensitizer or FXR agonist) plus an anti-inflammatory or antifibrotic drug to 725 
shut down key drivers of NASH synergistically.  726 
Liver-targeting technologies (e.g., using nanoparticles) may allow testing of more potent 727 
and specific approaches such as siRNA mediated knockdown of core pathogenic 728 
molecules/pathways, with a reduced risk of off-target liabilities. Alternatively, well-729 
established drugs could be repositioned as antifibrotic therapies, following identification 730 
using novel systems biology or phenotypic screening strategies. For example, 731 
nitazoxanide is an approved anti-parasitic agent that has shown promising antifibrotic 732 
activity in preclinical disease models and is currently being evaluated by Genfit in a 733 
phase 2 trial (NCT03656068) of patients with NASH and significant (F2/3) fibrosis.  734 
At present, there is a paucity of fibrolytic agents in development that may be effective at 735 
degrading mature hepatic scar. Even a modest effect on fibrosis remodeling may be 736 
sufficient to reduce portal hypertension and/or allow liver regeneration to occur 737 
endogenously. Alternatively, cell-based therapies may have potential for augmenting 738 
liver function in cirrhosis across the etiological spectrum [108]. Indeed, perhaps the field 739 
should focus more intently on approaches that target liver regeneration, rather than 740 
scarring per se, as a better strategy to improve how a patient with cirrhosis feels, 741 
functions and survives.  742 
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Figure legends 1126 
Figure 1. Clinical-pathological classification of cirrhosis and implications for 1127 
treatment. Cirrhosis consists of several stages, with a range of potential outcomes 1128 
based on the severity of histological and clinical correlates. Some cases of cirrhosis are 1129 
more likely to improve than others, especially those of recent onset, characterized by 1130 
relatively thin fibrous septa; here, etiological or specific antifibrotic therapies may induce 1131 
regression of cirrhosis. Conversely, mature hepatic scar with thick, acellular, heavily 1132 
cross-linked fibrous septa, such as those seen in established cirrhosis, may be 1133 
irreversible; here, treatment of cirrhosis complications or regenerative approaches are 1134 
likely to be more relevant. F1-4, fibrosis stage 1-4; (CS)PH, (clinically significant) portal 1135 
hypertension, HRS, hepatorenal syndrome. Figure modified with permission from 1136 
Wiley© from Garcia-Tsao et al, Now there are many (stages) where before there was 1137 
one: In search of a pathophysiological classification of cirrhosis, Hepatology (2010). 1138 
 1139 
Figure 2. Summary of synthetic drugs being evaluated in phase 2 or phase 3 trials 1140 
in cirrhosis.  Emerging drug candidates and mechanistic targets/pathways are 1141 
depicted. The majority relate to pathogenesis of non-alcoholic steatohepatitis. CCR2/5, 1142 
C-C chemokine receptor type 2/5; ER, endoplasmic reticulum; ROS, reactive oxidative 1143 
species; UPR, unfolded protein response; FFA, free fatty acids; SERBP-1, sterol 1144 
regulatory element-binding protein 1; SHP, small heterodimer partner; VLDL, very low 1145 
density lipoprotein; FGF19/21, fibroblast growth factor 19/21; FXR, farnesoid X receptor; 1146 
HSP47, heat shock protein 47; p38, p38 mitogen-activated protein kinase; JNK, c-Jun 1147 
N-terminal kinase; ACC, acetyl-CoA carboxylase; ASK-1, apoptosis signal-regulating 1148 
kinase 1; GLP-1,glucagon-like peptide 1; WNT, Wingless-related integration site; β-1149 
catenin, beta-catenin; Akt, protein kinase B; EGFR, epidermal growth factor receptor; 1150 
HSC, hepatic stellate cell; Z α1 AT, mutant alpha-1-antitrypsin Z; ECM, extracellular 1151 
matrix. 1152 
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